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Abstract
Background: Antigenic variation of influenza virus necessitates annual reformulation of seasonal influenza vaccines,
which contain two type A strains (H1N1 and H3N2) and one type B strain. We used a test negative case control
design to estimate influenza vaccine effectiveness (VE) against influenza by type and subtype over two consecutive
seasons in Victoria, Australia.
Methods: Patients presenting with influenza-like illness to general practitioners (GPs) in a sentinel surveillance
network during 2007 and 2008 were tested for influenza. Cases tested positive for influenza by polymerase chain
reaction and controls tested negative for influenza. Vaccination status was recorded by sentinel GPs. Vaccine
effectiveness was calculated as [(1 - adjusted odds ratio) × 100%].
Results: There were 386 eligible study participants in 2007 of whom 50% were influenza positive and 19% were
vaccinated. In 2008 there were 330 eligible study participants of whom 32% were influenza positive and 17% were
vaccinated. Adjusted VE against A/H3N2 influenza in 2007 was 68% (95% CI, 32 to 85%) but VE against A/H1N1
(27%; 95% CI, -92 to 72%) and B (84%; 95% CI, -2 to 98%) were not statistically significant. In 2008, the adjusted VE
estimate was positive against type B influenza (49%) but negative for A/H1N1 (-88%) and A/H3N2 (-66%); none was
statistically significant.
Conclusions: Type- and subtype-specific assessment of influenza VE is needed to identify variations that cannot be
differentiated from a measure of VE against all influenza. Type- and subtype-specific influenza VE estimates in
Victoria in 2007 and 2008 were generally consistent with strain circulation data.
Background
Vaccination is the cornerstone of influenza morbidity
and mortality prevention and many countries have
implemented publicly funded influenza vaccination pro-
grams for nationally defined high-risk groups [1]. As
part of its National Immunisation Program, in 2007 and
2008 the Australian Government provided free influenza
vaccination to all Australians aged 65 years and over,
and all Aboriginal and Torres Strait Islander people
aged 50 years and over or aged 15-49 years with medical
risk factors [2]. Influenza vaccination was also recom-
mended, but not funded, for: individuals aged six
months or older with conditions predisposing to severe
influenza, people who may potentially transmit influenza
to those at high risk of complications from influenza,
people providing essential services and travellers. Indivi-
dual industries are also advised to consider the benefits
of offering influenza vaccine in the workplace.
Only split virus and subunit trivalent inactivated influ-
enza vaccines are available for use in Australia against
two type A strains (one of each subtype H1N1 and
H3N2) and one type B strain which are frequently
replaced due to antigenic drift of circulating viruses
[2,3]. The World Health Organization (WHO) conducts
biannual consultations to recommend which influenza
virus strains should be included in the influenza vaccine
for the following northern and southern hemisphere
seasons [4]. The influenza virus compositions of the
2007 season vaccine were: A/New Caledonia/20/99
(H1N1)-like virus; A/Wisconsin/67/2005(H3N2)-like
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virus; and B/Malaysia/2506/2004-like virus (of the B/
Victoria/2/87 lineage) [5] and in 2008 were: A/Solomon
Islands/3/2006 (H1N1)-like virus; A/Brisbane/10/2007
(H3N2)-like virus; and B/Florida/4/2006-like virus (of
the B/Yamagata/16/88 lineage) [6].
Regular evaluation of vaccination programs by assess-
ment of effectiveness of vaccine to prevent disease is
important, particularly for influenza where vaccines
often change seasonally. Whilst clinical trials are the
ideal method for establishing vaccine efficacy, properly
designed observational studies provide a reliable and
more practical means of calculating vaccine effectiveness
(VE) under field conditions [7,8].
Victoria is Australia’s second most populous state with
a temperate climate and an annual influenza season that
usually occurs between May and September. Here we
describe assessment of the effectiveness of seasonal
influenza vaccine against laboratory confirmed influenza
infection over two consecutive influenza seasons (2007
and 2008) using a test negative case control study design
applied to a general practitioner (GP) sentinel surveil-
lance network. We have previously applied this method
to assess seasonal influenza VE against any laboratory
confirmed influenza [9] but here estimate the type- and
subtype-specific protection given by each seasonal influ-
enza vaccine. To our knowledge type and subtype VE
estimates have not previously been conducted for a
southern hemisphere season.
Methods
Sentinel surveillance
A sentinel general practice surveillance program for
influenza-like illness (ILI) and laboratory confirmed
influenza has been conducted in Victoria by the Victor-
ian Infectious Diseases Reference Laboratory (VIDRL)
and the Victorian Government Department of Health
since 1998. The program is comprised of a network of
GPs throughout Victoria who receive continuing profes-
sional development points from the Royal Australian
College of General Practitioners and the Australian Col-
lege of Rural and Remote Medicine for their participa-
tion. Each week during the influenza season, GPs report
cases of ILI as a proportion of total patients seen. Con-
sistent with established criteria, ILI was defined as his-
tory of fever, cough and fatigue/malaise [10]. The GPs
were also asked to collect a nose and throat swab from
patients presenting with ILI within four days of symp-
toms onset and forward to VIDRL for testing. Addi-
tional data on the patient’s age, sex, date of symptom(s)
onset, whether vaccinated and date of vaccination were
collected on the test request form. In 2007, 50 GPs par-
ticipated in the sentinel surveillance program which
operated for 34 weeks from 12 March (week 11) to 4
November (week 44) inclusive. There were 67 GPs in
the 2008 program which operated for 31 weeks from
14 April (week 16) to 16 November (week 46). The pro-
gram commenced earlier in 2007 to accommodate a
pilot varicella-zoster virus infection sentinel surveillance
program and finished later in 2008 to enable full capture
of ILI patients from a late season commencement.
Laboratory testing
All nose and throat swab samples were collected using
Copan dry swabs placed into virus transport medium.
Samples were tested by multiplex polymerase chain
reaction (PCR) for influenza A, influenza B, respiratory
syncytial virus, picornavirus, parainfluenza virus and
adenovirus using a conventional gel based assay [11]. A
conserved portion of the matrix gene and haemaggluti-
nin gene were targeted to identify influenza type A and
type B viruses respectively, with specific primers for
influenza A haemagglutinin H1 and H3 genes used to
determine subtype. Specimens were forwarded to the
WHO Collaborating Centre for Reference and Research
on Influenza for strain typing.
Ascertainment of cases and controls
Cases and controls were sampled prospectively through-
out the study period. A person with ILI who tested posi-
tive for influenza was classified as a case whilst a patient
with a negative test result, or who was positive for
another respiratory virus, was classified as a control. A
person selected as a control could become a case for a
subsequent separate clinical presentation during the sea-
son, but not vice versa. Patients were excluded from the
VE analysis if testing did not produce a result.
Data analysis and calculation of VE
Analyses were conducted using Stata (version 10.0; Sta-
taCorp LP). The chi squared test was used to compare
proportions, with p < 0.05 considered statistically signifi-
cant. Patients were excluded from the VE analysis if vac-
cination status was unknown, if the date of symptom(s)
onset was unknown or if there was an interval of greater
than four days between symptom onset and specimen
collection, based on the decreased likelihood of a posi-
tive result after this time [12,13]. For the purposes of
analysis, patients were considered not vaccinated if there
was less than 14 days between the dates of vaccination
and symptom onset.
Vaccine effectiveness was defined as [(1 - odds ratio) ×
100%] where the odds ratio is the odds of laboratory
confirmed cases being vaccinated divided by the odds of
test negative controls being vaccinated. In the test-nega-
tive case control design, the odds ratio estimates the
incidence density (rate) ratio because controls are
selected longitudinally throughout the course of the
study (i.e. by ‘density sampling’) [14,15]. The odds ratio
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in test-negative case control studies has also been shown
to approximate the risk ratio under conditions of vary-
ing attack rates and test sensitivity and specificity [16].
Logistic regression was used to calculate odds ratios and
95% confidence intervals (CI) that were adjusted for the
confounding variables of age (stratified into the age
groups 0-4 years, 5-19 years, 20-49 years, 50-64 years
and 65 years and over) and month of specimen collec-
tion. Sensitivity analyses were also conducted to deter-
mine the effect on VE estimates of: 1) not excluding
study participants if more than four days had elapsed
between symptom onset and specimen collection; 2)
excluding those vaccinated within 14 days of symptoms
onset and 3) classifying those vaccinated within 14 days
of symptoms onset as vaccinated.
Ethical considerations
Data in this study were collected, used and reported
under the legislative authorisation of the Victorian
Health (Infectious Diseases) Regulations 2001 and thus
did not require Human Research Ethics Committee
approval.
Results
General practitioners in the sentinel surveillance net-
work saw a total of 182,984 patients during the study
period in 2007, of which 1,226 (0.7%) had a reported
ILI. The ILI rate peaked in weeks 33 and 34 between
2.0% and 2.2% from a nadir of 0.04% in week 18. In
2008 there were 159,030 patients seen and a total of 876
(0.6%) reported to have an ILI. The weekly rate gener-
ally climbed steadily from 0.2% at the start of the 2008
study period in week 18 to a peak of 1.3% in week 35.
General practitioners collected nose and throat swabs
for testing from 480 (39%) and 407 (46%) patients with
ILI in 2007 and 2008 respectively. Of these, 223 (46%)
in 2007 and 117 (29%) in 2008 were positive for influ-
enza. The 2007 season was characterised by a high pro-
portion (58%) of type A/H3N2 influenza cases for which
limited strain typing data indicated a generally even split
between A/Brisbane/10/2007-like and A/Wisconsin/67/
2005-like viruses with a further 17% due to type B and
22% due to A/H1N1 for which all of those typed were
the A/Solomon Islands/3/2006-like strain (table 1). A
majority (56%) of influenza cases in 2008 were type B
with a further 36% due to type A/H3N2 although like
2007, a high proportion of specimens were unable to be
recovered or typed (table 1).
Following exclusion of cases for whom vaccination sta-
tus was unknown, symptom onset or specimen collection
dates were unknown or more than four days had elapsed
between symptom onset and specimen collection, there
were 386 (80%) and 330 (81%) study participants in
2007 and 2008 respectively (table 2). In 2008, a higher
proportion of influenza negative patients (17%) compared
to influenza positive patients (6%) were excluded because
more than four days had elapsed between symptom onset
and specimen collection (p = 0.004) whereas in 2007
there was no significant difference (14% and 8%; p =
0.10). There was no statistically significant difference in
whether or not study participants had a specimen col-
lected within four days of symptoms onset by age group
in either 2007 (p = 0.90) or 2008 (p = 0.09).
An epidemiological curve of influenza negative and
influenza positive patients eligible for inclusion in the
study (designated as controls and cases respectively)
shows an earlier detection of influenza in 2007 com-
pared to 2008, although there was only two weeks’ dif-
ference in the time from which influenza positive
patients were reported for more than three consecutive
weeks indicating the start of each season (Figure 1). In
addition to a higher number of study participants, the
2007 influenza season was longer (as defined by the
number of consecutive weeks in which influenza positive
cases were reported) and consisted of a higher propor-
tion of influenza positive study participants (n = 194;
50%) compared to 2008 (n = 106; 32%). The dominant
circulating influenza type and subtype varied over the
two seasons: 23% of cases in 2007 were A/H1N1, 60%
were A/H3N2 and the remainder were type B; the
respective proportions in 2008 were 4%, 36% and 57%
(table 3).
Table 1 Influenza positive swabs by subtype, year and
strain, 2007-2008
Influenza subtype and strain 2007 (%) 2008 (%)
A/H1N1
A/Solomon Islands/3/2006-likeb 21 (43) 0
A/New Caledonia/20/99-likea 0 0
Not recovered/no result 28e (57) 4 (100)
Total 49 (100) 4 (100)
A/H3N2
A/Brisbane/10/2007-likeb 12 (9) 4 (10)
A/Wisconsin/67/2005-likea 10 (8) 0
Not recovered/no result 108e (83) 38 (90)
Total 130 (100) 42 (100)
A/subtype not specified 8 6
B
B/Florida/4/2006-likeb 2 (5) 1 (2)
B/Malaysia/2506/2004-likea 3c (8) 1 (2)
B/Shanghai/361/2002-like 2d (5) 0
Not recovered/no result 30 (81) 63 (97)
Total 37 (100) 65 (100)
a 2007 vaccine strain
b 2008 vaccine strain
c includes 1 low reactor isolate
d includes 2 low reactor isolates
e 1 case positive for A/H1N1 and A/H3N2
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Age group, sex and month of swab collection distribu-
tions for controls and cases (including type and subtype
strata) are shown in table 3. There was no statistically
significant difference in the sex distribution between
controls and cases in either 2007 or 2008. In both years,
the numbers and proportions of controls and cases were
highest in the 20-49 years age group. Influenza type B
cases were significantly younger than controls in 2008
(p < 0.001); there were no other statistically significant
differences in age distribution between controls and
cases. With the exception of subtype A/H1N1 in 2008
for which there were only four cases, stratification by
month of swab collection revealed statistically significant
differences between cases and controls (range: p < 0.001
to p = 0.02) because of the higher proportion of type A
and type B cases identified in August and October 2007
respectively, and subtype A/H3N2 and type B in
August/September 2008.
A similar percentage of total study participants were
vaccinated in 2007 (19%) and 2008 (17%), although the
difference between vaccinated controls and vaccinated
cases was generally higher in 2007 (table 4). In 2008 a
higher proportion of cases of subtypes A/H1N1 and A/
H3N2 were vaccinated compared to controls. In both
years the proportion of cases and controls that were
vaccinated generally increased with age group. Among
Table 2 Study inclusion and exclusion criteria by year, 2007-2008
Criteria 2007 2008
Excluded Included Excluded Included
Inclusion
Respiratory swabs of ILI patients submitted by GPs 0 480 0 407
Exclusion
Influenza result unknown 0 480 0 407
Vaccination status unknown 8 472 4 403
Symptom onset to specimen collection interval unknown 41a 434 22a 384
> 4 days between symptom onset and specimen collection 50b 386 54 330
a includes 3 patients with unknown vaccination status
b includes 2 patients with unknown vaccination status
Figure 1 Case and control recruitment from influenza-like illness (ILI) presentations at sentinel general practices by week and year,
2007-2008.
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the study participants reported as vaccinated, only one
control in each year (0.5% in 2007 and 0.4% in 2008)
and no cases were vaccinated within 14 days of symp-
toms onset, for which there was no statistically signifi-
cant difference.
Following adjustment for month of swab collection
and age, there was a statistically significant protective
effect of influenza vaccine against all influenza in 2007
(VE = 59%; 95% CI, 25 to 78%) (table 5). The absence of
vaccinated cases and controls (table 4) meant VE was
unable to be estimated for several of the five age groups
so age was collapsed into three variables: children (0-19
years); working age adults (20-64 years); and the elderly
(65 years or older). When stratified by age group, the
Table 3 Cases and controls by age group, sex, month of swab collection, year and type/subtype, 2007-2008
2007 2008
Controls Influenza cases (%) Controls Influenza cases (%)
(%) All A/H1 A/H3 B (%) All A/H1 A/H3 B
Age group (years)
0-4 7 (4) 7 (4) 3 (7) 4 (3) 0 4 (2) 5 (5) 0 1 (3) 3 (5)
5-19 22 (11) 42 (22) 12 (27) 24 (21) 6 (23) 37 (17) 28 (27) 0 6 (16) 22 (37)
20-49 126 (66) 113 (58) 25 (56) 68 (58) 17 (65) 140 (63) 57 (54) 3 (75) 18 (47) 33 (56)
50-64 28 (15) 22 (11) 4 (9) 14 (12) 2 (8) 30 (13) 11 (10) 1 (25) 9 (24) 1 (2)
≥ 65 9 (5) 10 (5) 1 (2) 7 (6) 1 (4) 13 (6) 4 (4) 0 4 (11) 0
Sex
Female 89 (46) 96 (49) 20 (44) 62 (53) 12 (46) 105 (47) 55 (52) 1 (25) 19 (50) 34 (57)
Male 103 (54) 98 (51) 25 (56) 55 (47) 14 (54) 119 (53) 51 (48) 3 (75) 19 (50) 26 (43)
Month of swab collection
March 2 (1) 2 (1) 0 1 (< 1) 1 (4) 0 0 0 0 0
April 5 (3) 1 (< 1) 0 1 (< 1) 0 6 (3) 0 0 0 0
May 14 (7) 1 (< 1) 1 (2) 0 0 28 (13) 3 (3) 0 0 3 (5)
June 13 (7) 4 (2) 1 (2) 3 (3) 0 33 (15) 3 (3) 0 0 3 (5)
July 48 (25) 50 (26) 10 (22) 31 (27) 7 (27) 32 (14) 9 (8) 0 3 (8) 5 (8)
August 66 (34) 94 (48) 30 (67) 56 (48) 4 (15) 69 (31) 42 (40) 4 (100) 17 (45) 21 (35)
September 37 (19) 30 (15) 3 (7) 23 (20) 4 (15) 42 (19) 43 (41) 0 14 (37) 27 (45)
October 7 (4) 12 (6) 0 2 (2) 10 (38) 13 (6) 6 (6) 0 4 (11) 1 (2)
November 0 0 0 0 0 1 (< 1) 0 0 0 0
Total 192 194 45 117 26 224 106a 4 38 60a
a Age unknown for one case
Table 4 Cases and controls by year, age group, vaccination status and type/subtype, 2007-2008
Total study participants Total vaccinated (%) Controls vaccinated (%) Influenza cases vaccinated (%)
All A/H1 A/H3 B
2007
0-4 14 0 0 0 0 0 0
5-19 64 4 (6) 1 (5) 3 (7) 2 (17) 1 (4) 0
20-49 239 35 (15) 27 (21) 8 (7) 2 (8) 6 (9) 0
50-64 50 20 (40) 13 (46) 7 (32) 2 (50) 2 (14) 1 (50)
≥ 65 19 15 (79) 8 (89) 7 (70) 1 (100) 4 (57) 1 (100)
Total 386 74 (19) 49 (26) 25 (13) 7 (16) 13 (11) 2 (8)
2008
0-4 9 1 (11) 0 1 (20) 0 1 (100) 0
5-19 65 4 (6) 2 (5) 2 (7) 0 0 2 (9)
20-49 197 23 (12) 17 (12) 6 (11) 1 (33) 4 (22) 1 (3)
50-64 41 14 (34) 12 (40) 2 (18) 0 1 (11) 1 (100)
≥ 65 17 14 (82) 10 (77) 4 (100) 0 4 (100) 0
Total 330a 56 (17) 41 (18) 15 (14) 1 (25) 10 (26) 4 (7)
a Age unknown for one case
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statistically significant association in 2007 was restricted
to the 20-64 years age group. Furthermore, when exam-
ined by influenza type and subtype, and after adjusting
for age group and month of swab collection, the vaccine
was found to only be protective at a significant level
against the influenza A/H3N2 subtype (VE = 68%; 95%
CI, 32 to 85%), for which a statistically significant pro-
tective effect was maintained among the working age
adults age group only. In 2008, only the unadjusted
measure of VE against type B influenza was statistically
significant. Receiving vaccine was positively associated
with influenza illness for both A/H1N1 and A/H3N2
subtypes after adjustment for age and month of swab
collection in 2008 but neither of these associations was
statistically significant.
Sensitivity analyses were conducted to determine the
possible effect of assumptions about timing of swab
collection and vaccination status on the VE estimates.
The effect of not excluding study participants if more
than four days had elapsed between symptom onset and
specimen collection was a reduction of the adjusted
VE point estimates between 7% and 15% in 2007 and
between 5% and 35% in 2008. Study participants who
were known to be vaccinated within 14 days of symp-
tom onset (one control each in 2007 and 2008) were
classified as not vaccinated in the primary analysis. The
effect of excluding these cases or classifying them as
vaccinated resulted in variations of 0% to 7% around the
VE point estimates, but no changes in their relative sta-
tistical significance. However, collection of the ‘date of
vaccination’ field only commenced in 2008, in which it
was completed for 86 (91%) of the 94 vaccinated study
participants. In 2007, only 16 (22%) of the 73 study
participants reported as vaccinated had a recorded date
of vaccination.
Discussion
Although there was a low proportion of influenza cases
in this study for which strain typing results were avail-
able, the statistically significant estimate of 59% effec-
tiveness of influenza vaccine against all influenza in
2007 was generally consistent with Victorian state-wide
strain typing data which indicated a partial match of
circulating strains to those contained within the vaccine.
These data showed A/H3N2 to be the predominant cir-
culating subtype in 2007 (accounting for 56% of the
characterised isolates) of which 42% were the A/Wis-
consin/67/2005-like (vaccine) strain and the other 58%
were the A/Brisbane/10/2007-like strain [17]. When
stratified by subtype, the 2007 vaccine was 68% effective
(95% CI, 32 to 85%) against A/H3N2 infection and
although the A/Brisbane/10/2007-like strain appeared to
be the most dominant A/H3N2 strain, the relatively
high VE estimate is likely to be explained by the anti-
genic similarity between the A/Brisbane/10/2007-like
and A/Wisconsin/67/2005-like strains [18]. However,
stratified analysis did not indicate a significant protective
effect of the vaccine against type A/H1N1 or type B
infection in 2007, a finding which is supported by
apparent mismatch of circulating strains to vaccine
strains: 96% of the characterised A/H1N1 isolates were
the (non-vaccine) A/Solomon Islands/3/2006-like strain
whilst the characterised type B isolates were split
between B/Florida/4/2006-like (41%), B/Shanghai/361/
2002-like (35%) and B/Malaysia/2506/2004-like (24%)
[18].
Table 5 Crude and adjusted vaccine effectiveness of seasonal vaccine against influenza by year, age group and type/
subtype, 2007-2008
Influenza vaccine effectiveness (95% CI)
All A/H1 A/H3 B
2007
Crude 57 (27, 75) 46 (-28, 77) 64 (29, 81) 76 (-7, 94)
Adjusteda
0-19 -98 (-1906, 80) -333 (-5401, 66) -7 (-1850, 94) Not defined
20-64 64 (29, 82) 48 (-65, 84) 69 (29, 87) 85 (-19, 98)
≥ 65 74 (-283, 98) Not defined 84 (-156, 99) Not defined
All ages 59 (25, 78) 27 (-92, 72) 68 (32, 85) 84 (-2, 98)
2008
Crude 26 (-40, 61) -49 (-1367, 85) -59 (-254, 28) 68 (7, 89)
Adjusteda
0-19 -441 (-7774, 63) Not defined Not defined -314 (-6713, 75)
20-64 35 (-56, 73) -88 (-1936, 83) -17 (-255, 62) 71 (-32, 93)
≥ 65 Not defined Not defined Not defined Not defined
All ages 9 (-96, 58) -88 (-1936, 83) -66 (-349, 39) 49 (-58, 84)
a adjusted for month of swab collection
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With a non-significant point estimate of 9%, the
adjusted effectiveness of influenza vaccine against all
influenza in 2008 was considerably lower than in 2007.
The 2008 influenza season in both Victoria and across
Australia was of lower magnitude than 2007 and charac-
terised by a higher proportion of cases from influenza
type B virus [19,20]. This contrasts with a Western Aus-
tralian study of the 2008 influenza season, which like
Victoria was dominated by type B influenza virus with a
late peak, that found a much higher and statistically sig-
nificant VE point estimate of 58% (95% CI, 9 to 81%)
against all influenza [21]. Although this study was
restricted to children aged 6-59 months, for whom there
is a funded vaccination program in Western Australia,
the reason for such a large difference is unclear. Both
the sentinel general practice surveillance and other
state-wide subtyping data indicated an approximately
equal predominance of type A/H3N2 and type B viruses
in 2008 [20], although few cases from the sentinel sur-
veillance were able to be strain typed. Crude analysis
suggested that the vaccine was 68% effective at a statisti-
cally significant level against type B infection, although
after adjustment was 49% and not significant. This find-
ing is generally consistent with strain typing data
for isolates from across Victoria in which 42% were the
vaccine B/Florida/4/2006-like strain and 58% were B/
Malaysia/2506/2004-like, between which there was little
antigenic similarity given their different lineages (B/
Yamagata/16/88 and B/Victoria/2/87 respectively)
[19,20]. Strain typing of isolates sourced from elsewhere
in Victoria indicated that circulating A/H3N2 was exclu-
sively the A/Brisbane/10/2007-like strain and there was
very little circulation of any A/H1N1 strains.
This study demonstrates the importance of conducting
type- and subtype-specific assessment of influenza VE
given the considerable variation that cannot be differen-
tiated from a measure of VE against all influenza, despite
what strain typing of circulating isolates may suggest
about vaccine match/mismatch. A Canadian study that
measured influenza VE at the trivalent component level
during the 2006-2007 northern hemisphere season also
observed wide variation between type- and subtype-speci-
fic adjusted VE point estimates from 12% to 92% [22],
whilst two other observational studies in Wisconsin, Uni-
ted States of America (USA) and Canada also found
type-specific variation of VE point estimates from -35%
to 58% and 58% to 70% respectively [23,24]. However,
stratification of cases to assess type- and subtype-specific
influenza VE compromises power as evidenced in this
and the Canadian and USA studies. Insufficient power
also compromised the ability of our study to generate
more precise age group-specific estimates of VE, particu-
larly in 2008 despite the collapse of five age groups into
three. This was especially evident for those aged ≥ 65
years (the main risk group eligible for vaccination) in
which a protective - but not statistically significant -
effect against A/H3N2 influenza was demonstrated in
2007 but had too few cases to generate any VE estimates
in 2008, highlighting a previously recognised limitation
that the system is best suited to estimating VE amongst
working age adults who comprise the majority of the sur-
veillance population [9]. Thus, whilst the program func-
tions well as a representative surveillance system in
assessing magnitude and duration of influenza seasons,
further recruitment of sentinel GPs may be required to
sufficiently power VE calculations, particularly during sea-
sons of low magnitude or a dominant subtype.
A further limitation of this study is that the analysis
has not controlled for the potential confounding effect
of chronic or co-morbid conditions that are indicated
for influenza vaccination. Several Canadian observational
studies for which the specific confounding effect of co-
morbid conditions was reported resulted in variations of
the adjusted type- and subtype-specific VE estimates
against seasonal influenza about the crude estimate of
-23% to 7% [22,24], and an increase of 15% on the
crude seasonal VE against pandemic (H1N1) 2009 influ-
enza [25]. Whilst the confounding effect of co-existing
chronic medical conditions on VE estimates may be
modest and variable, these data will be included in the
patient questionnaire and analysis in future seasons as a
single variable. Pooling of confounders has been shown
as unlikely to result in residual confounding [26].
Although clinical trials are the ideal method to assess
vaccine efficacy, ethical, practical and financial consid-
erations have lead to the emergence of observational
studies - in particular case control studies such as this
one - to routinely assess influenza VE [22,24,27-29].
However, inherent in observational study designs are
biases that should be considered when interpreting and
generalising the results to other populations. This study
used test-negative control subjects which modelling,
assuming no bias, has shown generally slightly underes-
timates the true VE under most conditions of sensitivity,
specificity and influenza to non-influenza ILI attack
rates [16] but was higher than traditional control sub-
jects when assessed over three consecutive seasons [27].
Another consideration is the sampling frame of atten-
dees of general practices, for which a high proportion
are working-age adults probably representing the mid-
range of the clinical spectrum of influenza. More severe
presentations (particularly among children and the
elderly) are more likely to present to hospitals whilst
asymptomatic or mild infections, estimated to be 34%
[12], will not present to any medical facility. It is diffi-
cult to speculate how exclusion of cases from the per-
ipheries of the clinical spectrum might affect the VE
estimates, but highlights the importance of interpreting
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these results in the context of medically attended ILI in
the general practice setting.
Ascertainment bias of influenza status within the
study has been minimised by laboratory testing of all
study participants with an assay that is at least 90% sen-
sitive and 100% specific for influenza [11], and censoring
of observations for which there was greater than four
days between onset and specimen collection. Other fac-
tors, such as consistency of respiratory specimen collec-
tion, are difficult to quantify but may influence VE
estimates. Furthermore, participants’ illness and vaccina-
tion status are only known for the current season and
don’t account for cross-protection or prior immunity
provided by previous vaccination or influenza infection.
Conclusion
We have applied a test negative case control study
design to an established sentinel surveillance system to
assess type- and subtype-specific effectiveness of influ-
enza vaccine, which as yet is not routinely undertaken
elsewhere in Australia. We found that VE differed by
year, influenza type and subtype. Our analysis supple-
ments existing epidemiological and immunological data
about seasonal influenza and vaccination to assist with
evaluation of the influenza vaccination program.
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